Join us June 25-27, 2019 for Antibody Engineering & Therapeutics Digital Week, a global 4-day series of live educational webcasts and downloadable resources providing the latest insights for accelerating next generation antibodies to commercial success. To sponsor future digital events, contact or request details.

Day 1: Tuesday, June 25, 2019

Synthetic DNA Technologies Enable Antibody Discovery and Optimization
10am EDT / 3pm BST / 4pm CEST

Utilizing its proprietary DNA writing technology to create oligo pools, genes, and synthetic libraries, Twist Pharma, a division of Twist Bioscience, provides the biotechnology industry with an end-to-end antibody discovery solution.

This solution includes (1) a panel of high diversity synthetic antibody libraries, (2) a proprietary human anti-GPCR antibody phage display library focused on this validated target class, and (3) a Twist Antibody Optimization (TAO) platform for antibody affinity and developability optimization.


Aaron K. Sato, Ph.D.
Twist Bioscience, Biopharma

View More Details +

Oncolytic Vaccines Encoding T Cell Engagers: Tumor-targeted Delivery and Anti-tumor Synergy
12pm EDT / 5pm BST / 6pm CEST

Challenges in current cancer immunotherapy include increasing response rates and decreasing toxicity. We have developed tumor-selective oncolytic vectors for delivery of immunomodulators to avoid systemic exposure and mitigate toxicity. Furthermore, vector-mediated oncolysis serves as an in situ tumor vaccine, inducing synergistic anti-tumor immune responses. This talk highlights the versatility of our vector system and avenues for clinical translation.


Christine E. Engeland, M.D., Ph.D.
Physician-Scientist, Departments of Medical Oncology and Translational Oncology,
National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ)

View More Details +

Day 2: Wednesday, June 26, 2019

Accelerating target-to-lead antibody candidate selection using the Berkeley Lights Beacon Platform
9am EDT / 2pm BST / 3pm CEST

The development of biologics to novel therapeutic targets is hampered by current antibody discovery technologies that are laborious, time-consuming, and generate limited diversity. Here I will demonstrate how Berkeley Lights’ BeaconTM platform’s automated plasma cell antibody discovery workflow mines the vast immune repertoire to identify B cells producing rare, functional antibodies to difficult therapeutic targets in under 24 hours. Unlike other single-cell technologies, the Beacon platform enables users to perform multiple functional assays to enable selection of lead candidates against difficult therapeutic targets. The Beacon platform links phenotype-to-genotype at the single-cell level, thus simplifying downstream sequencing, cloning, and bioinformatics analysis.


Anupam Singhal, PhD
Senior Manager, Technology Development
Berkeley Lights, Inc.

View More Details +

"Antibodies to Watch” and More: Early- and Late-stage Clinical Development Trends
11am EDT / 4pm BST / 5pm CEST

The “Antibodies to watch” talks and papers focus on antibody therapeutics in late-stage clinical studies, as well as those is regulatory review and recently approved in the US and European Union. These topics will be discussed, along with trends observed in the burgeoning early-stage pipeline. Popular formats and mechanisms of action, as well as popular and obscure targets, for antibody therapeutics that recently entered the clinical pipeline will be included.


Janice Reichert, Ph.D.
Managing Director, Reichert Biotechnology Consulting
Executive Director, The Antibody Society

View More Details +

Day 3: Thursday, June 27, 2019

The Design, Optimisation and Manufacture of highly potent ADCs
10am EDT / 3pm BST / 4pm CEST

There is no one solution to the development of antibody drug conjugates and every target brings its own set of challenges to development such as reagent architecture which plays a critical role in the efficacy of an ADC.

This webinar will show how different conjugations technologies can be assessed side by side for efficacy allowing the ability to screen and rank multiple product candidates to optimise your ADC right from the beginning.

We will also look at what considerations you need to make during process development and manufacturing to ensure you get a homogeneous product.


Mark Frigerio
Director of Chemistry

View More Details +

REGISTER NOW – Please select the webcast(s) you wish to attend and enter your contact details

Day 1

Day 2

Day 3